Barclays PLC Reduces Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Barclays PLC decreased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 42.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 121,753 shares of the biopharmaceutical company's stock after selling 90,864 shares during the quarter. Barclays PLC owned about 0.21% of Agios Pharmaceuticals worth $4,000,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Summit Investment Advisors Inc. raised its position in shares of Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 394 shares during the last quarter. Sterling Capital Management LLC raised its holdings in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after buying an additional 1,587 shares during the last quarter. Kennedy Capital Management LLC lifted its stake in shares of Agios Pharmaceuticals by 281.4% in the fourth quarter. Kennedy Capital Management LLC now owns 111,098 shares of the biopharmaceutical company's stock worth $3,651,000 after buying an additional 81,971 shares in the last quarter. CenterBook Partners LP grew its holdings in shares of Agios Pharmaceuticals by 98.3% during the fourth quarter. CenterBook Partners LP now owns 305,599 shares of the biopharmaceutical company's stock valued at $10,042,000 after buying an additional 151,511 shares during the last quarter. Finally, Capula Management Ltd bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $685,000.

Insider Activity at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now directly owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock traded down $0.21 during mid-day trading on Friday, hitting $30.74. The company had a trading volume of 81,373 shares, compared to its average volume of 699,990. The company has a market capitalization of $1.78 billion, a P/E ratio of 2.73 and a beta of 0.83. The stock's 50 day moving average price is $29.91 and its 200-day moving average price is $37.92. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on AGIO. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 target price on the stock. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Finally, Scotiabank lowered their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Agios Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.